Home / Therapies / Meglitinides (page 2)

Meglitinides

Postprandial Hyperglycemia and Increased Cardiovascular Risk

Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in patients with Type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes …

Read More »

Metformin Reduces CardioVascular Mortality Risk by 26%

The widely prescribed metformin was alone among oral antidiabetic agents to show a significant effect on cardiovascular (CV) risk in a meta-analysis of 40 select controlled trials. It reduced CV mortality by 26% relative to any other antidiabetic agent or placebo, but there was no effect on all-cause mortality.

Read More »

Endo’s Issue Consensus Statement on Pre-Diabetes

It is good to see that there is more concern for those at risk for diabetes. The treatment of pre-diabetes requires intensive lifestyle modification and the use of metformin and acarbose for controlling glycemia for high-risk patients, declared a consensus statement issued by the American College of Endocrinology task force.

Read More »